Collaboration and License Agreements - Additional Information (Details)	1 Months Ended	3 Months Ended
	Mar. 31, 2020 USD ($) Target	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Collaboration And License Agreements [Line Items]
Collaboration and license revenue		$ 6,803,000	$ 3,021,000
Incurred costs		$ 29,546,000	19,184,000
Deferred revenue, current portion				$ 3,874,000
Maximum | Novartis Agreement
Collaboration And License Agreements [Line Items]
Ownership Interest		10.00%
Minimum | Novartis Agreement
Collaboration And License Agreements [Line Items]
Ownership Interest	10.00%
Novartis
Collaboration And License Agreements [Line Items]
License agreement date	Mar. 31, 2020
Upfront payment received	$ 20,000,000.0
Upfront payment receivable	$ 20,000,000.0
Negotiation period		180 days
Collaboration and license revenue		$ 5,800,000	3,000,000.0
Incurred costs		1,900,000	$ 1,000,000.0
Deferred revenue		$ 0
Novartis | Maximum
Collaboration And License Agreements [Line Items]
Number of targets identified | Target	3
Novartis | Research Funding
Collaboration And License Agreements [Line Items]
Upfront payment received	$ 10,000,000.0
Upfront payment receivable	$ 10,000,000.0